check
Bio | Shekh-Ahmad Lab

Bio

I have received my BSc degree in Pharmacy, in 2007; the MSc in Pharmaceutical sciences in 2011; and the PhD degree on the topic of “Design and pharmacokinetic/pharmacodynamic evaluation of novel CNS-active amide derivatives of valproic acid” in 2014, all from the School of Pharmacy, The Hebrew University of Jerusalem, Israel.
During my MSc and PhD studies, under the supervision of Dr. Eylon Yavin and Prof. Meir Bialer, I focused principally on developing new derivatives/analogues of existing antiepileptic drugs, and on performing stereoselective pharmacokinetic-pharmacodynamic relationship studies of individual stereoisomers of chiral aliphatic drugs.
In 2015, I joined the Department of Clinical and Experimental Epilepsy, University College London as a post-doctoral research fellow. I worked on identifying potential antioxidant treatment strategies that could translate into patient trials to prevent the development of epilepsy and associated comorbidities. In addition, I have worked on developing gene therapies for the treatment of temporal lobe epilepsy.
During my career I received many awards and fellowships, The Council for Higher Education and the Planning and Budgeting Committee (VATAT)-Israel Postdoc Fellowship, The Dimitris N. Chorafas Foundation award for an excellent PhD research, The "Yael Nussbaum Lev" for excellence in studies and research from School of Pharmacy, Institute of drug research, The Hebrew University, Excellence award for teaching and contribution to the life of the Institute of drug research from School of Pharmacy, The Hebrew University, and Excellence Award in B.Sc. degree studies.
I joined the School of pharmacy at the Faculty of medicine, The Hebrew University as a Senior Lecturer in July 2019. My current research interests include: the role of oxidative stress in neurological disorders, the multiple neuroprotective effects of Keap1/Nrf2 pathway, targeted drug delivery for CNS, AAV-based gene therapy for CNS diseases, and pharmacokinetics and pharmacodynamics of novel CNS active drugs.